Why is Aurobindo Pharma falling/rising?

As of 19-Jun, Aurobindo Pharma Ltd. is experiencing a decline in its stock price, currently at 1,083.25, reflecting a decrease of 23.8 points or 2.15%. The stock has been underperforming, having fallen consecutively for the last seven days, resulting in a total decline of 7.46% during this period. Additionally, it has underperformed its sector by 1.17% today. The stock is trading below its moving averages across various time frames, indicating a bearish trend. Despite a low debt-to-equity ratio and a reasonable price-to-book value, the stock has generated negative returns of 11.37% over the past year, which is concerning given that its profits have only increased by 5.3%. The decline in investor participation, with a significant drop in delivery volume, further exacerbates the stock's downward movement.
In the broader market context, Aurobindo Pharma's short-term performance has been notably worse than the benchmark, with a 1-week return of -6.06% compared to the Sensex's -0.40%. This underperformance is indicative of a lack of investor confidence, especially as the stock has not only lagged behind the market over the past year but also shows poor long-term growth prospects, with operating profit growth at only 5.00% over the last five years. The high institutional holdings at 41.57% suggest that knowledgeable investors are also cautious, contributing to the stock's current struggles in a market that has seen overall positive returns.